scispace - formally typeset
Search or ask a question
Institution

Roussel Uclaf

About: Roussel Uclaf is a based out in . It is known for research contribution in the topics: Alkyl & Alkoxy group. The organization has 1888 authors who have published 2338 publications receiving 36508 citations.
Topics: Alkyl, Alkoxy group, Aryl, Carbon, Carboxylic acid


Papers
More filters
Patent
Michel Fortin1, Daniel Frechet1, Gilles Hamon1, Simone Jouquey1, Jean-Paul Vevert1 
07 Jun 1991
TL;DR: In this paper, the authors discuss the role of the products of formula in the discovery of new products of the formule and propose a method to find the origin of the product of formula.
Abstract: PRECIS DE LA DIVULGATION: ABSTRACT OF THE DISCLOSURE: L'invention a pour objet les produits de formule (I): The invention relates to the products of formula (I): (I) dans laquelle: A represente reste d'un radical car-boxyclique ou heterocyclique sature ou insature, R (I) wherein: A is residue of a radical as boxyclique-or heterocyclic saturated or unsaturated, R represente alkyle, alkenyle ou alkynyle; represents alkyl, alkenyl or alkynyl; R1, R2, R3 et R4, representent hydrogene; R1, R2, R3 and R4 represent hydrogen; halogene; halogen; hydroxyle; hydroxyl; cyano; cyano; nitro; nitro; sulfo; sulfo; formyle; formyl; benzoyle; benzoyl; acyle; acyl; acyloxy; acyloxy; carboxy libre, salifie ou esterifie; carboxy free, salified or esterified; mercapto; mercapto; alkyle; alkyl; alkenyle; alkenyl; alkynyle; alkynyl; alkoxy; alkoxy; alkylthio; alkylthio; aryle; aryl; arylalkyle; arylalkyl; arylalkenyle; arylalkenyl; -(CH2)m-SO2-X-R14; - (CH2) m-SO2-X-R14; ou or dans lesquels: ou bien R6 et R7 ou R8 et R9, identiques ou differents, representent hydrogene, alkyle, alkenyle, aryle, arylalkyle, et -(CH2)m-SO2-X-R14 avec m represente 0 a 4, soit X-R4 represente NH2, soit X represente -NH-, -NH-CO-NH-ou -NH-CO- ou simple liaison et R14 represente alkyle, alkenyle ou aryle, ou bien R6 et R7 ou R8 et R9 forment avec azote auquel ils sont lies un radical carboxyclique ou heterocyclique, ou bien R8 et R9, identiques ou differents, representent acyle, alkyl ou arylsulfonyle; in which: either R6 and R7 or R8 and R9, identical or different, represent hydrogen, alkyl, alkenyl, aryl, arylalkyl, and - (CH2) m-SO2-X-R14 where m is 0 to 4, or X R4 represents NH2, or X represents -NH-, -NH-CO-NH-or -NH-CO- or single bond and R14 represents alkyl, alkenyl or aryl, or R6 and R7 or R8 and R9 together with nitrogen to which they are attached form a carbocyclic or heterocyclic radical, or R8 and R9, identical or different, represent acyl, alkyl or arylsulfonyl; R5 represente alkylene; R5 is alkylene; Y represente -Y1-B-Y2 dans lequel: Y1 represente aryle carboxyclique ou heterocyclique eventuellement substitues par R1, R2, R3 et R4, B represente: soit simple liaison entre Y1 et Y2, soit -CO-, -NH-CO-, -CO-NH- ou -O-(CH2)n- avec n representent 0 a 3, Y2 represente Y1, si B Y is -Y1-Y2-B wherein: Y 1 represents carbocyclic aryl or heterocyclic group optionally substituted by R1, R2, R3 and R4, B represents: either single bond between Y1 and Y2, or -CO-, -NH-CO-, -CO-NH- or -O- (CH2) n- with n represent 0 to 3, Y2 is Y1, if B represente une simple liaison, hydrogene, cyano, carboxy libre, salifie ou esterifie, etant entendu que: lorsque A represents a single bond, hydrogen, cyano, carboxy free, salified or esterified, it being understood that: when A represente phenyle eventuellement substitue par halogene, alkyle, alkoxy, acyle, carboxy libre ou phenyle substitue represents phenyl optionally substituted by halogen, alkyl, alkoxy, acyl, free carboxy or substituted phenyl par 5 atomes de fluor, R5 represente -CH2-, et Y represente -Y1-B-Y2 dans lequel Y1 represente phenyle non substitue et Y2 represente phenyle substitue en ortho par carboxy libre eventuellement salifie, tetrazolyle, trifluoro-methyl-sulfonamide et eventuellement halogene, alkyle, nitro ou methoxy, alors B represente -CO-NH- ou -O-(CH2)n- avec n representant 2 ou 3, lesdits produits de formule (I) etant sous toutes les formes isomeres possibles racemiques, enantiomeres et diastereoisomeres, ainsi que les sels d'addition avec les acides mineraux et organiques ou avec les bases minerales et organiques desdits produits de formule (I). by 5 fluorine atoms, R5 is -CH2-, and Y is -Y1-B-Y2 wherein Y1 represents unsubstituted phenyl and Y 2 is phenyl substituted ortho free carboxy optionally salified tetrazolyl, trifluoro-methyl-sulfonamide and optionally halogen, alkyl, nitro or methoxy, then B represents -CO-NH- or -O- (CH2) n- where n is 2 or 3, said products of formula (I) being in all the possible racemic, enantiomeric and diastereoisomers, and the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I). L'invention concerne egalement un procede de fabrication desdits produits, leur usage pour la preparation de medicaments, les compositions pharmaceutiques contenant lesdits produits et des intermediaires pour la preparation desdits produits. The invention also relates to a method for manufacturing said products, their use for the preparation of medicaments, pharmaceutical compositions containing said products and intermediates for the preparation of said products.

21 citations

Patent
22 Mar 1971
TL;DR: In this article, the authors proposed a framework for PREPARING PENTACYCLIC ALKLOIDS of General FormulA: 12-(CH3-OOC-),12-HO,13A-(CH 3-CH2-)-1,2,5,6,12,13-3H- INDOLO(3, 2,1-DE)PYRIDO (3,2.1-IJ)(1,5)NAPHTHYRIDINE
Abstract: PROCESS FOR PREPARING PENTACYCLIC ALKLOIDS OF GENERAL FORMULA: 12-(CH3-OOC-),12-HO,13A-(CH3-CH2-)-1,2,5,6,12,13-3H- INDOLO(3,2,1-DE)PYRIDO(3,2,1-IJ)(1,5)NAPHTHYRIDINE

21 citations

Journal ArticleDOI
TL;DR: A comparison of the incidence, pathology and endocrine properties of dog and human breast tumors is of interest in determining whether canine tumors can constitute a useful model for the study of clinical response to hormone therapy and whether, in recognized cases of hormone-dependence, pet bitches with mammary tumors should undergo endocrine therapy with synthetic hormones following mastectomy.

21 citations

Journal ArticleDOI
TL;DR: The pharmacokinetics and metabolism of moxestrol have been compared in the rat, dog and monkey and, in some instances, confronted with data simultaneously obtained for ethynl estradiol and previously obtained in humans.

21 citations

Journal ArticleDOI
TL;DR: The hydroxy substituent and the propynyl group in position 17 of the RU 486 series was replaced by a spiroether group, which is known to induce specific affinity for the progestin receptor in steroid series, and two new derivatives are selected, RU 46556 and RU 49295.

21 citations


Authors

Showing all 1888 results

NameH-indexPapersCitations
Fernand Labrie11088548308
Lionel H. Opie8451925964
Alain Bélanger7024416469
Michel J. Tremblay5327310485
Pierre Monsan512168049
Samir Z. Zard5057510739
Alejandro Aruffo4712314084
Samuel S.C. Yen47966865
Dominique Maraninchi471888108
Serge Erlinger461528200
Romain Lefebvre402215269
William B. Motherwell393056357
Jean-Pierre Raynaud381045075
André Lemay381144264
Patrick J. Creaven321023435
Network Information
Related Institutions (5)
Merck & Co.
48K papers, 1.9M citations

85% related

Novartis
50.5K papers, 1.9M citations

85% related

Pfizer
37.4K papers, 1.6M citations

84% related

Eli Lilly and Company
22.8K papers, 946.7K citations

84% related

AstraZeneca
23.4K papers, 938.2K citations

82% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20181
20114
20104
20091
20084
20072